• Home
• Responsibility
• CR Report 2005
• Managing CR
• Stakeholder engagement
• How we are responding

How we are responding

We reviewed our Corporate Responsibility Report in the light of stakeholder feedback and have addressed many of the points they made. This includes providing a better explanation of how Corporate Responsibility (CR) relates to our business strategy and more discussion of the challenges and dilemmas we have encountered.

Additional content has been provided this year in the following areas:

• Our approach to public policy and political lobbying. We are publishing our positions on key policy issues as well as our membership of trade associations and political donations in 2005.
• More on our marketing ethics policies and how we implement them, including data on the number of employees disciplined or dismissed for unethical conduct.
• Our approach to advertising to consumers.
• Our approach on payments to healthcare practitioners conducting GSK clinical trials.
• GSK’s approach to the authorship of research articles in medical journals in response to concerns about ‘ghost-writing’.
• Our relationship with patient advocacy groups. We are publishing a list of all the patient groups which received financial support from GSK in 2005.
• Our approach to preferential pricing in middle income countries and why we do not operate a tiered pricing system.
• Information about our pilot project to assess the benefits of extending preferential pricing to more products.
• More information on how we manage human rights standards in our supply chain.
• More information on our environment strategy and efforts to improve materials efficiency.

Sometimes we receive feedback and suggestions from stakeholders that we disagree with or are unable to accommodate without damaging the interests of the company and its shareholders. Where possible we explain the reasons for this, for example the need to use animals in research.

It is not possible to provide quantitative data or meaningful indicators for all areas of our CR performance. We will continue to review the performance indicators that we publish and build on them where possible.

We will continue to engage with stakeholders to understand their views of our approach to CR.

Back to top